5 months ago
SPOT
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 12%
#561 out of 4866 analysts
Average Return
+4.85%
Win Rate
41%78 out of 192
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-10 - 2023-05-09 | Buy |
Pharvaris NvPHVS | +206.28% | $8.12 | $24.87 | 2023-02-27 - 2024-02-26 | Buy |
Pharvaris NvPHVS | +198.29% | $8.75 | $26.10 | 2023-01-11 - 2024-01-10 | Buy |
Pharvaris NvPHVS | +194.90% | $8.62 | $25.42 | 2022-12-09 - 2023-12-08 | Buy |
Proqr Therapeutics NvPRQR | +188.44% | $0.79 | $2.27 | 2022-04-14 - 2023-04-13 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Mbx Biosciences IncMBX | 1 | Buy | $38.00 | +339.81% | Initiates Coverage On | 13 days ago |
Altimmune IncALT | 11 | Buy | $25.00 | +415.46% | Reiterates | 21 days ago |
Clearside Biomedical IncCLSD | 9 | Buy | $5.00 | +525.00% | Reiterates | a month ago |
Kalvista Pharmaceuticals IncKALV | 3 | Buy | $19.00 | +54.47% | Reiterates | a month ago |
Aura Biosciences IncAURA | 7 | Buy | $19.00 | +232.75% | Maintains | a month ago |
Skye Bioscience IncSKYE | 2 | Buy | $15.00 | +893.38% | Reiterates | a month ago |
Protagonist Therapeutics IncPTGX | 11 | Buy | $61.00 | +33.04% | Reiterates | a month ago |
Ocular Therapeutix IncOCUL | 15 | Buy | $19.00 | +140.20% | Maintains | 2 months ago |
Dbv Technologies SaDBVT | 13 | Buy | $10.00 | +14.29% | Reiterates | 2 months ago |
Pharvaris NvPHVS | 11 | Buy | $55.00 | +264.48% | Reiterates | 2 months ago |
Biocryst Pharmaceuticals IncBCRX | 7 | Buy | $18.00 | +130.18% | Reiterates | 2 months ago |
Astria Therapeutics IncATXS | 2 | Buy | $26.00 | +462.77% | Reiterates | 2 months ago |
Structure Therapeutics IncGPCR | 8 | Buy | $87.00 | +277.60% | Maintains | 2 months ago |
Crinetics Pharmaceuticals IncCRNX | 14 | Buy | $91.00 | +191.01% | Maintains | 2 months ago |
Mirum Pharmaceuticals IncMIRM | 9 | Buy | $74.00 | +87.67% | Reiterates | 2 months ago |
Madrigal Pharmaceuticals IncMDGL | 9 | Buy | $427.00 | +41.05% | Reiterates | 3 months ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Buy | $75.00 | +26.63% | Reiterates | 4 months ago |
Savara IncSVRA | 8 | Buy | $9.00 | +179.50% | Reiterates | 4 months ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | +49.84% | Maintains | 4 months ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | +11.29% | Reiterates | 4 months ago |
Proqr Therapeutics NvPRQR | 5 | Buy | $8.00 | +492.59% | Reiterates | 4 months ago |
Spruce Biosciences IncSPRB | 7 | Hold | $3.00 | +2,207.69% | Downgrades | 4 months ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | -17.85% | Downgrades | 5 months ago |
Allakos IncALLK | 6 | Buy | $3.00 | +820.25% | Reiterates | 7 months ago |
Sagimet Biosciences IncSGMT | 8 | Buy | $32.00 | +1,154.90% | Maintains | 8 months ago |
Larimar Therapeutics IncLRMR | 11 | Buy | $25.00 | +950.42% | Reiterates | a year ago |
Rallybio CorpRLYB | 11 | Buy | $8.00 | N/A | Reiterates | a year ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 2 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.